MA Testa, DC Simonson - Diabetes Care, 2007 - Am Diabetes Assoc RESULTS—Overall treatment satisfaction (0–100) increased by 13.2 ± 1.1 units for inhaled insulin
(baseline = 63.3 ± 1.2) compared with 1.7 ± 0.8 for subcutaneous insulin injection (baseline =
64.1 ± 1.2, P < 0.0001). All 12 satisfaction subscales favored inhaled insulin (all P < 0.01), ... Cited by 12 - Related articles - BL Direct - All 8 versions
- ►diabetesjournals.org PA Hollander, A Krasner, S Klioze, P Schwartz, W … - Diabetes Care, 2007 - Am Diabetes Assoc Weight gain is commonly seen when patients are started on subcutaneous (SC) insulin. In the
UK Prospective Diabetes Study, those assigned insulin gained 4 kg more than those assigned
conventional therapy at 10 years (1). Given that the majority of patients with type 2 ... Cited by 10 - Related articles - BL Direct - All 5 versions
[CITATION] Inhaled insulin–single-dose pharmacokinetics of inhaled human insulin (Exubera® …
JE Gern, CK Stone, M Nakano, DB Muchmore, A … - Clinical Pharmacology & …, 2007 - nature.com The suitability of employing AIR Inhaled Insulin (AIR Insulin; AIR is a registered trademark of
Alkermes) during acute upper respiratory tract infection (URI) has not been determined.
Twenty-one healthy, non-diabetic subjects were enrolled in a single-sequence, ... Cited by 4 - Related articles - All 3 versions
[CITATION] Effect of intercurrent respiratory tract infections on inhaled human insulin (Exubera …
CJ Bailey, AH Barnett - British Medical Journal, 2007 - bmj.com On 18 October Pfizer announced that it would withdraw the first inhaled insulin, Exubera, from
the market, as sales were too low. In January 2006 Pfizer bought the worldwide rights to Exubera
from Sanofi-Aventis for $1.3bn (£0.6bn; 0.9bn), and in August 2006 the product was ... Cited by 6 - Related articles - BL Direct - All 2 versions
N Freemantle, T Strack… - Trials, 2006 - biomedcentral.com Common deterrents to insulin therapy for both physicians and patients are the complexity and
burden of daily injections. In January 2006, the first inhaled human insulin (INH, Exubera ®
(insulinhuman [rDNA origin])InhalationPowder) was approved for use in adult patients ... Cited by 8 - Related articles - Cached - All 9 versions
JS Skyler, L Jovanovic, S Klioze, J Reis, W Duggan - Diabetes Care, 2007 - Am Diabetes Assoc RESULTS—The mean ± SEM annual rates of change between months 0 and 24 were −0.051
± 0.005 l/year with EXU and −0.034 ± 0.005 l/year with SC insulin (significant mean difference
−0.017 ± 0.007 l/year [90% CI −0.028 to −0.005]) for FEV 1 and −0.437 ± 0.073 ml · min ... Cited by 37 - Related articles - BL Direct - All 9 versions
